单剂量和多剂量伊曲康唑对P-糖蛋白底物非索非那定药代动力学的影响。
Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
作者信息
Shimizu Mikiko, Uno Tsukasa, Sugawara Kazunobu, Tateishi Tomonori
机构信息
Department of Clinical Pharmacology, Hirosaki University School of Medicine, Hirosaki, Japan.
出版信息
Br J Clin Pharmacol. 2006 Sep;62(3):372-6. doi: 10.1111/j.1365-2125.2006.02689.x. Epub 2006 Jun 23.
Abstract
AIMS
We determined whether or not the extent of drug interaction of fexofenadine by itraconazole is time-dependent.
METHODS
In a randomized two-phase crossover study, itraconazole was administered orally for 6 days, and, on days 1, 3 and 6, fexofenadine was administered simultaneously. On another occasion, fexofenadine was administered alone.
RESULTS
Itraconazole increased fexofenadine AUC(0, infinity), and the % change for difference was 178% (95% CI 1235, 3379), 205% (95% CI 1539, 3319) and 169% (95% CI 1128, 2987) on days 1, 3 and 6 of the 6 day treatment, respectively.
CONCLUSIONS
The extent of drug interaction by itraconazole was not time-dependent.
摘要
目的
我们确定了伊曲康唑与非索非那定的药物相互作用程度是否具有时间依赖性。
方法
在一项随机两阶段交叉研究中，口服伊曲康唑6天，在第1、3和6天同时给予非索非那定。在另一个时间段，单独给予非索非那定。
结果
伊曲康唑增加了非索非那定的AUC(0,∞)，在6天治疗的第1、3和6天，差异的百分比变化分别为178%（95%可信区间1235,3379）、205%（95%可信区间1539,3319）和169%（95%可信区间1128,2987）。
结论
伊曲康唑的药物相互作用程度不具有时间依赖性。
相似文献
1
Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.单剂量和多剂量伊曲康唑对P-糖蛋白底物非索非那定药代动力学的影响。
Br J Clin Pharmacol. 2006 Sep;62(3):372-6. doi: 10.1111/j.1365-2125.2006.02689.x. Epub 2006 Jun 23.
2
Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.伊曲康唑对非索非那定药代动力学相互作用不存在剂量依赖性效应。
Drug Metab Dispos. 2006 Nov;34(11):1875-9. doi: 10.1124/dmd.106.011023. Epub 2006 Aug 23.
3
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.伊曲康唑对非索非那定药代动力学和药效学的影响与多药耐药基因1（MDR1）基因多态性的关系
Clin Pharmacol Ther. 2005 Aug;78(2):191-201. doi: 10.1016/j.clpt.2005.04.012.
4
Pharmacokinetics of fexofenadine enantiomers in healthy subjects.非索非那定对映体在健康受试者中的药代动力学。
Chirality. 2007 Mar;19(3):223-7. doi: 10.1002/chir.20370.
5
Clinical pharmacokinetics of fexofenadine enantiomers.特非那定对映异构体的临床药代动力学。
Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):69-74. doi: 10.1517/17425250903382615.
6
Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.三种转运抑制剂维拉帕米、西咪替丁和丙磺舒对非索非那定药代动力学的不同影响。
Clin Pharmacol Ther. 2005 Jan;77(1):17-23. doi: 10.1016/j.clpt.2004.08.026.
7
Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.伊曲康唑和地尔硫䓬对P-糖蛋白底物非索非那定药代动力学的影响。
Br J Clin Pharmacol. 2006 May;61(5):538-44. doi: 10.1111/j.1365-2125.2006.02613.x.
8
Time-dependent interaction between lopinavir/ritonavir and fexofenadine.洛匹那韦/利托那韦与非索非那定之间的时间依赖性相互作用。
J Clin Pharmacol. 2006 Jul;46(7):758-67. doi: 10.1177/0091270006288733.
9
Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver.圣约翰草对非索非那定在离体灌注大鼠肝脏中处置的影响。
J Pharm Pharmacol. 2009 Aug;61(8):1037-42. doi: 10.1211/jpp/61.08.0007.
10
Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography.非索非那定和西替利嗪的中枢效应：使用11C-多塞平正电子发射断层扫描测量精神运动表现、主观嗜睡和脑组胺H1受体占有率
J Clin Pharmacol. 2004 Aug;44(8):890-900. doi: 10.1177/0091270004267590.
引用本文的文献
1
Clinical Pharmacokinetics of Fexofenadine: A Systematic Review.非索非那定的临床药代动力学：一项系统评价。
Pharmaceutics. 2024 Dec 20;16(12):1619. doi: 10.3390/pharmaceutics16121619.
2
Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.伊曲康唑和氟康唑对瓦立美他司特药代动力学的影响：一项在健康受试者中进行的开放标签、I 期研究。
Clin Transl Sci. 2023 Nov;16(11):2153-2162. doi: 10.1111/cts.13613. Epub 2023 Sep 13.
3
Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjects.评估在健康受试者中与 filgotinib 相关的通过 P-gp、OCT2 和 MATE1/2K 介导的潜在药物相互作用。
Clin Transl Sci. 2022 Feb;15(2):361-370. doi: 10.1111/cts.13152. Epub 2021 Sep 25.
4
Efficacy of histamine H1 receptor antagonists azelastine and fexofenadine against cutaneous Leishmania major infection.组胺 H1 受体拮抗剂氮卓斯汀和非索非那定对皮肤利什曼原虫感染的疗效。
PLoS Negl Trop Dis. 2020 Aug 10;14(8):e0008482. doi: 10.1371/journal.pntd.0008482. eCollection 2020 Aug.
5
A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.一种用于定量预测外排转运体和细胞色素介导的相互作用的通用模型：在 P-糖蛋白和细胞色素 3A4 中的应用。
Clin Pharmacokinet. 2019 Apr;58(4):503-523. doi: 10.1007/s40262-018-0711-0.
6
Evaluation of P-Glycoprotein Inhibitory Potential Using a Rhodamine 123 Accumulation Assay.使用罗丹明123蓄积试验评估P-糖蛋白抑制潜力。
Pharmaceutics. 2016 Apr 12;8(2):12. doi: 10.3390/pharmaceutics8020012.
7
Effects of danshen ethanol extract on the pharmacokinetics of fexofenadine in healthy volunteers.丹参乙醇提取物对健康志愿者体内非索非那定药代动力学的影响。
Evid Based Complement Alternat Med. 2014;2014:473213. doi: 10.1155/2014/473213. Epub 2014 Nov 3.
8
Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.基于生理的药代动力学建模和体内[I]/K(i)可准确预测P-糖蛋白介导的达比加群酯药物-药物相互作用。
Br J Pharmacol. 2014 Feb;171(4):1043-53. doi: 10.1111/bph.12533.
9
Fruit juice inhibition of uptake transport: a new type of food-drug interaction.果汁抑制摄取转运：一种新型的食物-药物相互作用。
Br J Clin Pharmacol. 2010 Nov;70(5):645-55. doi: 10.1111/j.1365-2125.2010.03722.x.
10
Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.克霉唑口含片对口服和静脉注射咪达唑仑药代动力学的影响。
Br J Clin Pharmacol. 2010 Feb;69(2):160-6. doi: 10.1111/j.1365-2125.2009.03559.x.
本文引用的文献
1
Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection.采用柱切换高效液相色谱-紫外检测法灵敏测定人血浆中的伊曲康唑及其活性代谢物。
Ther Drug Monit. 2006 Aug;28(4):526-31. doi: 10.1097/00007691-200608000-00007.
2
Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.伊曲康唑和地尔硫䓬对P-糖蛋白底物非索非那定药代动力学的影响。
Br J Clin Pharmacol. 2006 May;61(5):538-44. doi: 10.1111/j.1365-2125.2006.02613.x.
3
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.伊曲康唑对非索非那定药代动力学和药效学的影响与多药耐药基因1（MDR1）基因多态性的关系
Clin Pharmacol Ther. 2005 Aug;78(2):191-201. doi: 10.1016/j.clpt.2005.04.012.
4
Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans.有机阴离子转运多肽（OATP）家族转运体对非索非那定在人体肝脏摄取中的作用。
Drug Metab Dispos. 2005 Oct;33(10):1477-81. doi: 10.1124/dmd.105.004622. Epub 2005 Jul 13.
5
Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1).非索非那定的药代动力学与SLCO1B1基因（编码有机阴离子转运多肽1B1）的多态性相关。
Br J Clin Pharmacol. 2005 May;59(5):602-4. doi: 10.1111/j.1365-2125.2005.02354.x.
6
Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection.液相色谱法结合荧光检测测定人血浆中的非索非那定。
J Pharm Biomed Anal. 2004 Jun 29;35(4):937-42. doi: 10.1016/j.jpba.2004.02.036.
7
Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human.人源pH敏感有机阴离子转运多肽OATP-B的功能特性
J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. doi: 10.1124/jpet.103.060194. Epub 2003 Nov 10.
8
Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol.伊曲康唑可提高塞利洛尔的血浆浓度，但葡萄柚汁会使其大幅降低。
Clin Pharmacol Ther. 2003 Mar;73(3):192-8. doi: 10.1067/mcp.2003.26.
9
Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells.单羧酸、大中性氨基酸、胆汁酸和肽转运蛋白以及P-糖蛋白在MDCK和Caco-2细胞中的功能特性
J Pharm Sci. 2002 Dec;91(12):2622-35. doi: 10.1002/jps.10264.
10
Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir.非索非那定在Caco-2细胞中的转运：维拉帕米和利托那韦的抑制作用。
J Clin Pharmacol. 2002 Nov;42(11):1269-74. doi: 10.1177/009127002762491370.
Zotero 插件